Compare FELE & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FELE | CRSP |
|---|---|---|
| Founded | 1944 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.0B |
| IPO Year | 1995 | 2016 |
| Metric | FELE | CRSP |
|---|---|---|
| Price | $102.71 | $47.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 17 |
| Target Price | ★ $103.50 | $70.29 |
| AVG Volume (30 Days) | 282.4K | ★ 1.7M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $2,131,250,000.00 | $289,590,000.00 |
| Revenue This Year | $6.84 | $807.72 |
| Revenue Next Year | $3.43 | $172.52 |
| P/E Ratio | $134.61 | ★ N/A |
| Revenue Growth | 5.44 | ★ 9169.85 |
| 52 Week Low | $89.54 | $44.12 |
| 52 Week High | $115.82 | $78.48 |
| Indicator | FELE | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 41.22 |
| Support Level | $101.97 | $44.82 |
| Resistance Level | $109.70 | $59.83 |
| Average True Range (ATR) | 2.90 | 1.67 |
| MACD | -0.23 | -0.15 |
| Stochastic Oscillator | 10.33 | 34.28 |
Franklin Electric Co Inc designs, manufactures, and distributes water and fuel pumping systems, composed of submersible motors, pumps, electronic controls, water treatment systems, and related parts and equipment. It has three segments; The Water Systems segment designs, manufactures and sells motors, pumps, drives, electronic controls, monitoring devices, and related parts and equipment for use in groundwater, water transfer, and wastewater, The Energy Systems segment designs, manufactures and sells pumps, pipe, sumps, fittings, vapor recovery components, electronic controls, monitoring devices, and related parts and equipment for use in fueling system applications and the Distribution segment sells and provides presale support and specifications to the installing contractors.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.